Body Vision Medical Pens Distribution Agreements for LungVision
License out/in
Body Vision Medical (BVM) recently announced it has signed exclusive distribution agreements with Prism Technologies Limited, Paragon Care, and Kral Medical Solutions to open the Hong Kong, Macao and entire Greater Bay Area, Australia and New Zealand, and Romania markets to the LungVision real-time intraoperative CT imaging system.
The LungVision system, which is AI-powered, can take X-ray images from any C-arm device and turn them into real-time intraoperative CT scans, which helps bronchoscopist’s visualize pulmonary lesions and ensure precise biopsy during diagnostic bronchoscopy, according to BVM.
The company stated that the exclusive distribution agreements signify their commitment to giving lung patients greater access to the latest AI-powered imaging technology.
"We view these partnerships as a pivotal stride towards democratizing Body Vision's LungVision and giving lung patients worldwide access to the latest in AI-powered imaging technology,” said David Webster, CEO of BVM, in a press release announcing the agreement. “In many parts of the world with high lung cancer incidence, limited access to advanced medical solutions has translated into lower patient survival rates. With innovative yet cost-effective solutions like LungVision, we hope to challenge and change that status quo."
Looking forward over the next three years, the company said it aims to expand access to the system in 60 new markets.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.